Bristol Myers Squibb Reports Three-Year CheckMate-649 Data for Opdivo in Gastric Cancer

Bristol Myers Squibb today presented three-year overall survival data from the Phase 3 CheckMate-649 trial evaluating Opdivo (nivolumab) plus chemotherapy in patients with previously untreated advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma. The data showed that the overall survival benefit of Opdivo was maintained at three years, with 11% of patients in the Opdivo arm alive at three years compared to 6% in the chemotherapy arm.